Electromed’s Q3 FY2026: A Quiet Epidemic of Growth in Homecare Tech

Quarter in focus: momentum, not noise

Electromed, Inc., the maker of SmartVest airway clearance therapy, delivered a Q3 FY2026 that reads like a well-tuned inhaler: steady, purposeful, and just enough to remind you the market for home-based respiratory care is not a mirage. Net revenues rose 18.4% year over year to $18.6 million, led by an 18.6% surge in the core direct homecare line to $16.7 million. The company also posted a record quarterly net income of $3.0 million, or $0.35 per diluted share, up 58.8% from the prior-year period.

The operating income figure—$3.8 million—climbed 76% versus the same quarter last year and represented about 20.3% of net revenues. In short: more revenue, more leverage, more oxygen in the P&L.

Key metrics and what they signal

• Revenue growth: 18.4% to $18.6 million in Q3 FY2026, from $15.7 million in the prior-year quarter.
• Operating income: $3.8 million, up 76.0% year over year.
• Net income: $3.0 million, or $0.35 per diluted share, up 58.8% from $1.9 million, or $0.21 per diluted share in the same period a year ago.
• Gross focus: direct homecare revenue up 18.6% to $16.7 million (vs. $14.1 million prior year).
• All figures are for the three months ended March 31, 2026; comparative figures are for March 31, 2025.
• Strategic backdrop: 86% of covered lives in the United States are under contract; manufacturing optimization completed, positioning the company to scale.

Executive commentary

“I’m happy to report that Electromed has delivered its 14th consecutive quarter of year-over-year revenue and profit growth,” said Jim Cunniff, President and Chief Executive Officer. “We continue to invest in our sales and fulfillment teams to drive greater prescription volumes and faster delivery of our SmartVest therapy to more patients. With 86% of covered lives under contract and our manufacturing optimization complete, we’re well-positioned to capture the opportunity in the underserved bronchiectasis market. As we look ahead, our strong operational foundation, strategic investments, and continued focus on education and awareness give us confidence in sustaining our trajectory of profitable growth.”

What this portends for Electromed and sector peers

The quarter reinforces a theme we’ve watched unfold in homecare-enabled medical devices: growth is driven as much by contract adoption and operational gravity as by product innovation. Electromed’s 86% contracted US covered-lives backdrop creates a built-in revenue floor, while manufacturing optimization acts as a lever to expand margins as volumes rise.

For Electromed’s sector peers—companies serving chronic respiratory care and home-based therapeutics—the message is twofold. First, a durable revenue base aided by payer or provider contracts can meaningfully lift profitability even when the top-line pace accelerates modestly. Second, the emphasis on direct homecare segments suggests investors may reward firms that digitize logistics, scale fulfillment, and shorten cycles from prescription to patient delivery.

In terms of earnings discipline, the reported EPS of $0.35 on $3.0 million net income provides a clean snapshot of leverage now in play. The release does not publish an EPS consensus or a formal revenue forecast, which means market expectations may grapple with earnings-surprise risk as analysts align models to ongoing contract dynamics and utilization trends.

Bottom line and potential catalysts

Electromed’s momentum is anchored in a clear, improving unit economics story: growing core revenue, higher operating leverage, and a broadened payer footprint. The absence of a stated revenue forecast or explicit EPS consensus in the filing invites investors to triangulate with external estimates, creating a window for earnings surprise as consensus adjusts to the company’s disclosed trajectory.

Looking ahead, investors will watch three levers: continued expansion of the direct homecare line, the pace of contract attainment across more regions or payers, and whether manufacturing optimization translates into sustainable margin expansion as volumes scale.